Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC3402 plus durvalumab in advanced hepatocellular carcinoma
CTR20233016Phase 2Terminated
- Sponsor
- Zhikang Hongyi
- Start
- Sep 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BC3402, durvalumab in hepatocellular carcinoma (HCC), sponsored by Zhikang Hongyi. Started Sep 2023; status: terminated.
02
Drugs
BC3402durvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20233016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233016.